Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Orbit Discovery Ltd.. (9/11/23). "Press Release: Orano Med and Orbit Discovery Enter Collaboration to Discover Novel Targeted Radioligand Therapies for Cancer". Texas & Oxford.

Organisations Organisation Orbit Discovery Ltd.
  Today T-Cypher Bio Ltd.
  Group T-Cypher Bio Ltd.
  Organisation 2 Orano Med SASU
  Group Orano (Group)
Products Product Lead-212 (212Pb) Targeted Alpha Therapy
  Product 2 drug discovery services
Persons Person Butt, Neil (Orbit Discovery 202106– CEO before Iontas + Abzena + Antitope)
  Person 2 Dodet, Julien (Orano 202309 CEO of Orano Med)
     


Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 (212Pb) Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals. Under the terms of the agreement, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.

Radioligand therapies rely on a simple concept: combining the ability of biological molecules such as peptides to target cancer cells with the short-range cell-killing capabilities of radioisotopes. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. It opens new perspectives for patients with difficult to treat cancers and the global market of targeted radiotherapies is expected to grow at a CAGR of 30% between 2023 and 2030.

The collaboration will harness the capabilities of Orbit’s peptide display engine to identify peptide candidates specific to tumour-associated targets. The proprietary technology enables the screening of large peptide collections through the combination of DNA encoded libraries and bead-based presentation. Orbit’s peptide display engine is uniquely equipped to address soluble targets and targets in situ, both on and in cells, allowing for significantly faster discovery times of relevant peptide leads based on affinity screens and/or functional screens. Orano Med will focus on subsequent development of the peptides for clinical use after conjugation with lead-212, one of the most promising alpha emitter isotopes for use in radioligand therapy.

Dr Neil Butt, Chief Executive Officer, Orbit Discovery, said: “We’re delighted to continue expanding our existing portfolio of partners by collaborating with Orano Med who have a strong track record of discovering novel radiopharmaceuticals” He continued: “We’re very proud of our proprietary screening platform at Orbit and acknowledge its role in empowering the next wave of peptide therapeutics.”

Julien Dodet, Chief Executive Officer, Orano Med, commented: “Since the inception of Orano Med, we have recognised the value of collaboration.” He added: “In our strategy to develop and deliver 212Pb Targeted Alpha Therapy for cancer patients, we’re delighted to work with Orbit Discovery and leverage its technology and expertise in peptide ligand discovery to build our pipeline of radiotherapies.”


Orbit Discovery will be attending Boulder Peptide Foundation in California, 18th – 21st September.

For further information, please visit: www.orbitdiscovery.com and www.oranomed.com


About Orano Med SAS

Orano Med is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). Alpha decay results in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission, which leads to an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. Orano Med develops several treatments using 212Pb combined with various targeting agents. The company has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe.

For more information, please visit: www.oranomed.com

Follow us on LinkedIn: www.linkedin.com/company/areva-med-llc/


About Orbit Discovery

Orbit Discovery Ltd is a peptide discovery company focused on the use of novel bead and microfluidic technology platforms to improve the throughput of functional screening. The Orbit technologies encompass target protein expression and purification, including multi-spanning membrane proteins; affinity screening to identify panels of target binding therapeutic candidates; and functional screening in cell-based assays. Orbit’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics for Partners and collaborators, these parties encompass large scale pharmaceutical and biotechnology companies. Orbit Discovery is based in the Oxford Science Park and benefits from the expertise and experience of its founders, Professor Graham Ogg (University of Oxford) and Professor Terry Rabbits (the Institute of Cancer Research)

For more information, please visit: www.orbitdiscovery.com

Follow us on LinkedIn: www.linkedin.com/company/orbit-discovery/


ENDS


Notes to Editors


For further information please contact:

Orbit Discovery Ltd
Dr Neil Butt
Tel: +44(0)1865 749234
Email: neil.butt@orbitdiscovery.com

Zyme Communications
Dr Maria Spyrou
Tel: +44(0)7707 049 640
Email: maria.spyrou@zymecommunications.com

Orano Med
Sophie Letournel
Strategy, Governance and Communication Director
Tel: +33 6 38 44 34 11
Email: sophie.letournel@orano.group

   
Record changed: 2024-01-20

Advertisement

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for T-Cypher Bio Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top